Stabilizing the enzyme in fish odor syndrome
Fish odor syndrome, or trimethylaminuria, is a disease in which the liver cannot break down the smelly chemical trimethylamine, or TMA, that is produced by enzymes from bacteria residing in the gut. There is no cure for fish odor syndrome, which gives people an unpleasant fishy smell that can affect breath, sweat, urine and vaginal fluids.

Our research team at the University of Warwick is working to prevent the syndrome through studying the enzyme in the gut that produces trimethylamine.
Fish odor syndrome starts when an enzyme pathway in the gut called CntA/B produces TMA. The enzyme breaks down a TMA precursor called L-carnitine, which is found in dairy, fish and meat. If an individual lacks a functional liver enzyme called FMO3, they cannot degrade TMA into a non-smelly chemical form, trimethylamine oxide, or TMAO. The TMA then builds up in the body and ends up in bodily fluids.
In a recent paper, published in the Journal of Biological Chemistry, our team in Yin Chen's lab at Warwick's School of Life Sciences focused on the CntA protein of the CntA/B enzyme, to stabilize and study it.
CntA/B is a notoriously hard enzyme to study, but once it was stabilized, we were able to gain insight into how CntA perceives its L-carnitine substrate with a 3D crystal structure model, and by studying the complete electron transfer pathway, we could see how the protein is able to turn over TMA.
Now that we understand how exactly TMA is produced in the gut and that the enzyme can be inhibited, there are grounds for further research into future discovery of drugs targeting the TMA-producing enzyme in the human gut.
We have identified novel, drug-like inhibitors that can inhibit CntA function and thus TMA formation with the potential to attenuate TMA formation in the gut microbiome. This is vital not only for people who have fish odor syndrome, but also because TMA can accelerate atherosclerosis and heart disease.
This article was adapted from a University of Warwick press release. Read the original here.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Spider-like proteins spin defenses to control immunity
Researchers from Utrecht University discovered two distinct binding modes of a spider-shaped immune inhibitor found in serum.

A biological camera: How AI is transforming retinal imaging
AI is helping clinicians see a more detailed view into the eye, allowing them to detect diabetic retinopathy earlier and expand access through tele-ophthalmology. These advances could help millions see a clearer future.

AI in the lab: The power of smarter questions
An assistant professor discusses AI's evolution from a buzzword to a trusted research partner. It helps streamline reviews, troubleshoot code, save time and spark ideas, but its success relies on combining AI with expertise and critical thinking.

Training AI to uncover novel antimicrobials
Antibiotic resistance kills millions, but César de la Fuente’s lab is fighting back. By pairing AI with human insight, researchers are uncovering hidden antimicrobial peptides across the tree of life with a 93% success rate against deadly pathogens.

AI-designed biomarker improves malaria diagnostics
Researchers from the University of Melbourne engineered Plasmodium vivax diagnostic protein with enhanced yield and stability while preserving antibody-binding, paving the way for more reliable malaria testing.

Matrix metalloproteinase inhibitor reduces cancer invasion
Scientists at the Mayo Clinic engineered a TIMP-1 protein variant that selectively inhibits MMP-9 and reduces invasion of triple-negative breast cancer cells, offering a promising tool for targeted cancer research.